Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial

Fig. 1

CONSORT flow diagram of recruited patients and follow-up. Men diagnosed with PC by trans-rectal prostate needle biopsy underwent a bone scan. If patients had bone metastasis and agreed to participate in the trial, they were assigned to receive ADT alone, TOPADT or RAPADT in a 1:1:1 ratio (n = 15)

Back to article page
\